obesity glp-1 news today ADA 2026 confirmed what many of us have been anticipating for years. We're entering a new era of medicine: triple agonists, oral GLP-1s, monthly injections, and therapies targeting obesity, diabetes, and glp-1 drugs news today Market

Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, Lautrup S, Hasan-Olive MM, Caponio D, Dan X, Rocktschel P, Croteau DL, Akbari M, Greig NH, Fladby T, Nilsen H, Cader MZ, Mattson MP, Tavernarakis N, Bohr VA (2019) Mitophagy inhibits amyloid- and tau pathology and reverses cognitive deficits in models of Alzheimers disease

Heavy metal and chemical toxicities often cause adverse reactions in the body that are difficult to shake off

Some forecasters have predicted that the online weight-loss-drug market will grow to $150 billion in the next five years

Potential for Serotonin Syndrome Although rare, serotonin syndrome can occur when too much serotonin accumulates in the body

Far in the lead is Lilly with its late-stage orforglipron, which in a June 2023 Phase II readout achieved weight loss between 9.4% and 14.7% at 36 weeks

Having sufficient levels of B12 has been linked to improved response to antidepressant medications, as several studies have shown